ibandronic acid has been researched along with Neoplasms in 22 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 9 (40.91) | 18.2507 |
2000's | 7 (31.82) | 29.6817 |
2010's | 5 (22.73) | 24.3611 |
2020's | 1 (4.55) | 2.80 |
Authors | Studies |
---|---|
Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 1 |
Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
Curtis, D; Lu, Y; Qiao, D; Wang, Z; Wen, X; Yao, Y; Zhao, H | 1 |
Gerner, C; Grunt, T; Haider, F; Karlic, H; Proestling, K; Thaler, R; Varga, F | 1 |
Galiti, D; Galitis, E; Karampeazis, A; Labropoulos, S; Migliorati, C; Nicolatou-Galitis, O; Razis, E; Sgouros, J; Tsimpidakis, A | 1 |
Antràs, L; Diel, IJ; Duh, MS; Green, J; Köppler, H; Neary, M; Smith, M; Weide, R; Wintfeld, N | 1 |
Grätz, KW; Jacobsen, C; Metzler, P; Obwegeser, J; Rössle, M; Zemann, W | 1 |
Berenson, JR | 1 |
Bergström, B; Pecherstorfer, M; Rizzoli, R; Steinhauer, EU; Wetterwald, M | 1 |
Heidenreich, A; Ohlmann, CH | 1 |
Guay, DR | 1 |
Kouloulias, V; Kouskouni, E; Mystakidou, K; Parpa, E; Stathopoulou, E; Vlahos, L | 1 |
Baumgartner, G; Blind, E; Pecherstorfer, M; Raue, F; Schilling, T; Ziegler, R; Zimmer-Roth, I | 1 |
Clemens, MR; Ghielmini, M; Jaeger, P; Krahl, D; Manegold, C; Scharla, SH; Schöter, KH; Thiébaud, D; Wüster, C | 1 |
Blind, E; Meinel, T; Raue, F; Wüster, C; Ziegler, R | 1 |
Body, JJ; Clemens, MR; Degardin, M; Herrmann, Z; Huss, HJ; Manegold, C; Pecherstorfer, M; Steinhauer, EU; Thiébaud, D; Thürlimann, B; Tubiana-Hulin, M; van Eijkeren, M | 1 |
Irzyniec, T; Kokot, F; Wiecek, A; Wnuk, RS | 1 |
Burckhardt, P; Fioroni, P; Juillerat, L; Leuenberger, P; Ludwig, H; Markert, M; Pecherstorfer, M; Sauty, A; Thiebaud, D; Zimmer-Roth, I | 1 |
Burckhardt, P | 1 |
Balfour, JA; Dooley, M | 1 |
Body, JJ; Bundred, N; Clemens, MR; Degardin, M; Eghbali, H; Herrmann, Z; Huss, HJ; Manegold, C; Pecherstorfer, M; Rizzoli, R; Rückert, F; Steinhauer, EU; Thiébaud, D; Thürlimann, B; Tubiana-Hulin, M | 1 |
Body, JJ | 1 |
9 review(s) available for ibandronic acid and Neoplasms
Article | Year |
---|---|
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2015 |
Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review.
Topics: Aged; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Fatal Outcome; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Neoplasms; Periodontal Diseases; Radiography, Panoramic; Retrospective Studies; Tooth Extraction; Zoledronic Acid | 2015 |
Treatment of hypercalcemia of malignancy with bisphosphonates.
Topics: Bone Resorption; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2002 |
Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Infusions, Intravenous; Neoplasms; Osteoporosis; Product Surveillance, Postmarketing; Risk Factors | 2004 |
Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Interactions; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Neoplasms; Osteoporosis | 2006 |
Ibandronate in oncology.
Topics: Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Neoplasms; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic | 1997 |
Ibandronate.
Topics: Animals; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Neoplasms; Osteitis Deformans; Osteoporosis, Postmenopausal | 1999 |
Current and future directions in medical therapy: hypercalcemia.
Topics: Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandronic Acid; Imidazoles; Neoplasms; Pamidronate; Zoledronic Acid | 2000 |
6 trial(s) available for ibandronic acid and Neoplasms
Article | Year |
---|---|
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Neoplasms; Pamidronate; Treatment Outcome | 2003 |
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Male; Neoplasms; Prognosis; Prospective Studies; Quality of Life | 2008 |
Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia.
Topics: Aged; Bone Resorption; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Injections, Intravenous; Male; Middle Aged; Neoplasms | 1993 |
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
Topics: Adult; Aged; Aged, 80 and over; Bone Resorption; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Nausea; Neoplasms; Recurrence; Regression Analysis; Thrombocytopenia; Treatment Outcome | 1996 |
Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.
Topics: Aged; Aged, 80 and over; Bone Resorption; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Interleukin-1; Interleukin-6; Male; Middle Aged; Neoplasms; Pamidronate; Tumor Necrosis Factor-alpha | 1996 |
Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Topics: Absorption; Calcium; Cohort Studies; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Kidney Tubules; Male; Middle Aged; Neoplasms; Parathyroid Hormone-Related Protein; Proteins; Recurrence; Syndrome; Treatment Outcome | 1999 |
7 other study(ies) available for ibandronic acid and Neoplasms
Article | Year |
---|---|
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diphosphonates; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Epigenesis, Genetic; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Mevalonic Acid; MicroRNAs; NADP; Neoplasms; Protein Processing, Post-Translational; Simvastatin; Vitamin D | 2015 |
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Cancer Care Facilities; Creatinine; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Middle Aged; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Renal Insufficiency; Retrospective Studies; Zoledronic Acid | 2009 |
Osteopathology induced by bisphosphonates and dental implants: clinical observations.
Topics: Actinomycosis; Administration, Intravenous; Administration, Oral; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cone-Beam Computed Tomography; Debridement; Dental Implants; Diphosphonates; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Male; Mandible; Mandibular Neoplasms; Maxilla; Neoplasms; Osteomyelitis; Osteoporosis; Pamidronate; Risk Factors; Time Factors; Zoledronic Acid | 2013 |
Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Life Expectancy; Male; Middle Aged; Neoplasms; Pamidronate; Parathyroid Hormone-Related Protein; Proteins; Survival Rate | 1994 |
Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
Topics: Adult; Aged; Calcium; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Neoplasms; Parathyroid Hormone-Related Protein; Proteins | 1993 |
[Use of third generation bisphosphonates in treatment of neoplastic hypercalcemia].
Topics: Adult; Aged; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypercalcemia; Ibandronic Acid; Male; Middle Aged; Neoplasms | 1995 |